The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1290
July 14, 2008
View Complete Issue         Table of Contents 2019 
Varenicline (Chantix) Warnings: Risk Versus Benefit
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Varenicline (Chantix) Warnings: Risk Versus Benefit
July 14, 2008 (Issue: 1290)
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Varenicline (Chantix) Warnings: Risk Versus Benefit
Article code: 1290a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.